Pipeline
| Indication | Program / Regulatory Pathway | Preclinical | Phase I | Phase II | Phase III | NDA | FDA Approval | Partner |
|---|---|---|---|---|---|---|---|---|
| Opioid Overdose | NARCAN® Nasal Spray | Approved |  | |||||
| Opioid Overdose | OPNT003 Nalmefene Nasal Spray |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
| |
| Alcohol Use Disorder | OPNT002 Opioid Antagonist Nasal Spray |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
| |
| Acute Cannabinoid Overdose | OPNT004 Drinabant (CB-1 Antagonist) |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|  |
| Opioid Use Disorder | OPNT005 Heroin Vaccine: hapten + liposome adjuvant |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|  |
| Opioid Use Disorder | OPNT006 Opioid Antagonist Implant |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
| |